Downstaging or downsizing: Time for a new staging system in advanced colorectal cancer?

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2702-2706

  Poston, Graeme ^a   Adam, Rene ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; DRUG EFFICACY; HEALTH CARE SYSTEM; HUMAN; LIVER FIBROSIS; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; NOTE; PALLIATIVE THERAPY; PATIENT SELECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; STEATOSIS; TREATMENT RESPONSE; ARTICLE; COLORECTAL TUMOR; DRUG CONTRAINDICATION; LIVER RESECTION; LIVER TUMOR; METASTASIS; PATHOLOGY;

COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING;

EID: 33745515416     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.8404     Document Type: Note

References (71)

1. Hughes KS: Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection. Surgery 103:278-288, 1988
2. Scheele J, Stang R, Altendorf-Hofmann A, et al: Resection of colorectal liver metastases. World J Surg 19:59-71, 1995
3. Rougier P, Milan C, Lazorthes F, et al: Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 82:1397-1400, 1995
4. Scheithauer W, Rosen H, Kornek G-V: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755, 1993
5. Poston GJ, Adam R, Alberts S, et al: OncoSurge: A strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23:7125-7134, 2005
6. Abdalla E, Barnett CC, Doherty D, et al: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 137:675-680, 2002
7. Vauthey JN, Chaoui A, Do KA, et al: Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations. Surgery 127:512-519, 2000
8. Elias D, Liberale G, Vernerey D, et al: Hepatic and extrahepatic colorectal metastases: When respectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12:900-909, 2005
9. Jaeck D: The significance of hepatic pedicle lymph node metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol 10:1007-1011, 2003
10. Nordlinger B, Guiguet M, Vaillant J-C, et al: Surgical resection of colorectal carcinoma metastases to the liver. Cancer 77:1254-1262, 1996
11. Fong Y, Fortner J, Sun R, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-316, 1999
12. Figueras J, Valls C, Rafecas J, et al: Resection rates and effect of postoperative chemotherapy on survival after colorectal liver metastases. Br J Surg 88:980-985, 2001
13. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759-766, 2002
14. Abdalla E, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818-825, 2004
15. Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722, 2005
16. Kanemitsu Y, Kato T, Hirai T, et al: Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91:112-120, 2004
17. Elias D, Sideris L, Pocard M, et al: Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 11:274-280, 2004
18. Yoshidome H, Ito H, Kimura F, et al: Surgical treatment for extrahepatic recurrence after hepatectomy for colorectal metastases. Hepatogastroenterology 51:1805-1809, 2004
19. Inoue M, Ohta M, Iuchi K, et al: Benefits of surgery for patients with pulmonary metastases from colorectal cancer. Ann Thorac Surg 78:238-244, 2004
20. Chiche L: When is first-line resection of hepatic metastases indicated? Gastroenterol Clin Biol 27:B11-B13, B41-B61, 2003 (suppl 2)
21. Poston GJ: Radiofrequency ablation of colorectal liver metastases: Where are we really going? J Clin Oncol 23:1342-1344, 2005
22. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
23. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
24. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
25. Cals L, Rixe O, Francois E, et al: Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 15:1018-1024, 2004
26. Saltz LB, Meropol NJ, Loehrer PJ, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
27. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
28. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
29. Ardalan B, Livingstone A, Franceschi D, et al: A phase II study of irinotecan, fluoroxuridine and leucovorin (IFLUX) as first-line chemotherapy in advanced colorectal cancer. J Clin Oncol 23:270s, 2005 (suppl 16, abstr 3599)
30. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520, 1996
31. Akasu T, Moriya Y, Takayama T: A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: Hepatic resection after hepatic arterial infusion chemotherapy and portal embolization. Jpn J Clin Oncol 27:331-335, 1997
32. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353, 2001
33. Giacchetti S, Itzuki M, Gruia G, et al: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669, 1999
34. Meric F, Patt YZ, Curley SA, et al: Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 7:490-495, 2000
35. Shankar A, Leonard P, Renaut AJ, et al: Neo-adjuvant therapy improves respectability rates for colorectal liver metastases. Ann R Coll Surg Engl 83:85-88, 2001
36. Gil-Delgado MA, Guinet F, Castaing D, et al: Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am J Clin Oncol 24:101-105, 2001
37. Wein A, Reidel C, Kockerling F, et al: Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluotouracil and folinic acid. Ann Oncol 12:1721-1727, 2001
38. Rivoire M, de Cian F, Meeus P, et al: Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95:2283-2292, 2002
39. Miyanari N, Mori T, Takahashi K, et al: Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 45:1503-1509, 2002
40. Falcone A, Masi G, Cupini S, et al: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20:4006-4014, 2002
41. Ho WM, Mok TSK, Ma BB, et al: Liver resection after irinotecan (CPT-11), 5-fluorouracil (5FU) and folinic acid (FA) in patients (pts) with unresectable liver metastases (Mets) from colorectal cancer (CRC). Proc Am Soc Clin Oncol 22:312, 2003 (abstr 1253)
42. Alberts SR, Donohue JH, Mahoney MR, et al: Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 22:263, 2003 (abstr 1053)
43. Zelek L, Bugat R, Cherqui D, et al: Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 14:1537-1542, 2003
44. Pozzo C, Basso M, Cassano A, et al: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal carcinoma patients. Ann Oncol 15:933-939, 2004
45. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644-657, 2004
46. Rougier P, Raoul J-L, van Laethem J-L, et al: Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal cancer. J Clin Oncol 22:248, 2004 (suppl 14, abstr 3513)
47. Tabernero JM, van Cutsem E, Sastre J, et al: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR): Preliminary results. J Clin Oncol 22:248, 2004 (suppl 14, abstr 3512)
48. de la Camara J, Rodriguez J, Rotellar F, et al: Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol 23:268, 2004 (suppl 14, abstr 3593)
49. Leonard GS, Fong Y, Jarnagin W, et al: Liver resection after hepatic infusion (HAD plus systemic oxaliplatin (OXAL) combination in pretreated patients with extensive unresectable colorectal liver metastases. J Clin Oncol 23:255, 2004 (suppl 14, abstr 3542)
50. Falcone A, Masi G, Cupini S, et al: Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC). J Clin Oncol 23:258, 2004 (suppl 14, abstr 3553)
51. Fisher GA, Kuo T, Cho CD, et al: A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 23:248, 2004 (suppl 14, abstr 3514)
52. Gruenberger T, Schuell B, Kornek G, et al: Neoadjuvant chemotherapy for resectable colorectal cancer metastases: Impact on magnitude of liver resection and survival. J Clin Oncol 23:269, 2004 (suppl 14, abstr 3598)
53. Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 23:9243-9249, 2005
54. Diaz-Rubio E, Tabernero J, van Cutsem E, et al: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol 23:254s, 2005 (suppl 16, abstr 3535)
55. Abad A, Anton A, Massuti B, et al: Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU: Final results of a phase II study. J Clin Oncol 23:275s, 2005 (suppl 16, abstr 3618)
56. Bouchahda M, Tanaka K, Adam R, et al: Three-drug chemotherapy via hepatic artery as salvage treatment for patients with liver-only metastases from colorectal cancer. J Clin Oncol 23:275s, 2005 (suppl 16, abstr 3616)
57. Martoni A, Pinto C, di Fabio F, et al: Phase II randomized trial on protracted 5-fluoruracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian FOCA study. J Clin Oncol 23:275s, 2005 (suppl 16, abstr 3617)
58. Moosmann N, Kern W, Waggershausser T, et al: Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastases from colorectal cancer: Final analysis of a phase I/II study. J Clin Oncol 23:278s, 2005 (suppl 16, abstr 3628)
59. Folprecht G, Lutz MP, Seufferlein T, et al: Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase I/IIa study. J Clin Oncol 23:281s, 2005 (suppl 16, abstr 3640)
60. Sufferlein T, Dittrich C, Riemann J, et al: A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP)(FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR): Preliminary results. J Clin Oncol 23:281s, 2005 (suppl 16, abstr 3644)
61. Garassino I, Carnaghi C, Rimassa L, et al: Definitive results of hybrid chemotherapy with intravenous (IV) oxaliplatin (OXA) and folinic acid (FA), and intra-hepatic infusion (HAI) of 5-fluorouracil (5-FU) in patients with colorectal liver metastases. J Clin Oncol 23:288s, 2005 (suppl 16, abstr 3670)
62. Shimonov M, Hayat H: Alternating hepatic artery chronotherapy with CPT-11 and systemic chronotherapy with 5-FU/FA+carboplatin for metastatic colorectal cancer confined to the liver: A phase II study. J Clin Oncol 23:297s, 2005 (suppl 16, abstr 3707)
63. Seium Y, Stupp R, Ruhstaller T, et al: Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: A phase I-II study. Ann Oncol 16:762-766, 2005
64. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005
65. Elias D, Youssef O, Sideris L, et al: Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86:4-9, 2004
66. Schrag D, Weiser M, Schattner M, et al: An increasingly common challenge: Management of the complete responder with multi-focal metastatic colorectal cancer. J Clin Oncol 23:1799-1802, 2005
67. Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases. Ann Surg 240:1052-1061, 2004
68. Vauthey J-N, Abdalla EK: Unresectable hepatic colorectal metastases: Need for new surgical strategies. Ann Surg Oncol 13:5-6, 2006
69. American Joint Committee on Cancer: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer Verlag, 2002
70. Rubbia-Brandt L, Audard V, Sartoretti P, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460-466, 2004
71. Bilchik AJ, Poston GJ, Curley SA, et al: Neoadjuvant chemotherapy for metastatic colon cancer: A cautionary note. J Clin Oncol 23:9073-9078, 2005